...therapeutics company Highlight Therapeutics S.L appointed Carlos Pava as executive chairman; he was CEO of Immune Design Corp....

...The company has also augmented its pipeline through its buyouts of Tilos Therapeutics Inc. and Immune Design Corp....

...at Radius Health Inc. (NASDAQ:RDUS); and CMO Sergey Yurasov, who was SVP and CMO of Immune Design Corp....

...to develop diagnostics to detect antimicrobial resistance. In February, Merck announced a deal to acquire Immune Design Corp....

...Nightstar Therapeutics plc (NASDAQ:NITE) 3/4/19 $877.0 NA NA $877.0 Merck & Co. Inc. ( NYSE:MRK) Immune Design Corp....

...Merck & Co. Inc. (NYSE:MRK) will acquire cancer vaccine company Immune Design Corp. (NASDAQ:IMDZ) to boost its cancer...
...20, before the deal was announced. Immune Design gained $4.40 (310%) to $5.82 on Feb. 21. Immune Design...
...unlikely to improve survival in synovial sarcoma (see "Immune Design Deprioritizes Synovial Sarcoma Compound CMB305" ). Immune Design's...

...Merck & Co. Inc. (NYSE:MRK) will acquire cancer vaccine company Immune Design Corp. (NASDAQ:IMDZ) to boost its cancer...
...$1.42 Wednesday, before the deal was announced. Immune Design gained $4.40 (310%) to $5.82 on Thursday. Immune Design...
...unlikely to improve survival in synovial sarcoma (see "Immune Design Deprioritizes Synovial Sarcoma Compound CMB305" ). Immune Design's...

...company will seek to partner CMB305 to explore further development of the compound in sarcoma. Immune Design...
...portfolio prioritization will extend its cash runway into 2021. In an Aug. 1 SEC filing, Immune Design...
...and the GLA-SE adjuvant. Immune Design previously reported interim data from the Phase II trial (see "Immune Design...

...also co-founded cancer synthetic lethality company Tango Therapeutics Inc., and Baltimore helped found immunotherapy companies Immune Design Corp....
...Inc., South San Francisco, Calif. Grail Inc., Menlo Park, Calif. Gritstone Oncology Inc., Emeryville, Calif. Immune Design Corp....

...In March, Immune Design Corp. (NASDAQ:IMDZ) reported data from 25 patients with cancer/testis antigen 1B (NY-ESO-1; CTAG1B)-positive soft...
...not yet been reached in the subset of 14 patients with synovial sarcoma. According to Immune Design...
...chemotherapeutic agents is 12.4-13.5 months for STS patients and 11.7 months for synovial sarcoma patients. Immune Design...